News · 26 weeks55-8%
2025-12-282026-06-21
Mix3390d
- SEC Filings23(70%)
- Other9(27%)
- Analyst1(3%)
Latest news
25 items- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- PRFresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma FirepowerIssued on behalf of Conexeu Sciences Inc.A clutch of new directors with Fortune 500 finance, M&A, and aesthetics pedigrees signals that the newly public tissue-regeneration company is building for commercialization — in one of medicine's most consequential frontiers.RENO, Nev., June 16, 2026 /CNW/ -- American News Group News Commentary — There is a well-worn pattern in the life sciences: a company spends years on the science, goes public, and then — in the critical window right after listing — races to assemble the kind of leadership bench that can turn a promising platform into a real business. The names a young company recruits in that window say a great deal about its ambitions. On June 1
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- PRA Fresh FDA Catalyst Is Putting Regenerative Wound Care in FocusNEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary — In healthcare, the market tends to perk up when a company stops speaking in broad platform language and starts showing real progress toward the FDA. That is what makes the latest update from Conexeu Sciences Inc. (NASDAQ:CNXU) — issued from Reno, Nevada on June 8, 2026 — worth a closer look. A newly Nasdaq-listed regenerative-tissue company carrying a market capitalization in the hundreds of millions, Conexeu has moved its lead CXU™ wound-care program further into manufacturing scale-up and regulatory preparation as it works toward a planned first-quarter 2027 510(k) submission. Companies mentioned: Conexeu Scien
- PRSmith+Nephew announces first clinical cases with the next generation CORI◊XT Handheld Robotics Platform across knee and shoulder arthroplastySmith+Nephew ((LSE: SN, NYSE:SNN), the global medical technology company, announces the completion of the first clinical cases performed using the next‑generation CORI◊ XT Handheld Robotics Platform, marking an important milestone in the clinical introduction of its latest handheld robotics technology. CORI XT Handheld Robotic Platform is designed to be the single handheld robotics platform for all orthopaedic needs - partial to revision knee, hip*, and anatomic and reverse shoulders - with a footprint tailored to the unique needs of hospitals and ambulatory surgical suites settings. These early cases represent the first use of CORI XT Platform across both knee and shoulder arthroplasty a
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- ANALYSTSmith & Nephew downgraded by KeplerKepler downgraded Smith & Nephew from Buy to Hold
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- PRSmith+Nephew launch next generation LEAF™ Patient Monitoring System – an innovative pressure injury prevention platform delivering proven clinical impactSmith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, announces the US launch of next generation LEAF♢ Patient Monitoring System, a data-driven pressure injury prevention platform designed to help health care providers tackle the growing burden of hospital-acquired pressure injuries (HAPIs) by strengthening protocols and outcomes. The LEAF System uses a wearable sensor to monitor patient mobility and provide real-time turn status updates, helping to improve workflow efficiency, turn quality, and protocol adherence.1-3 Every year, approximately 60,000 annual deaths in the US are attributed to HAPIs,4 placing a $26.8B annual burden on the nationwide economy.5 For individu
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- PRA Reno Biotech Just Rang the Nasdaq Bell — Here's Why the Whole Regenerative-Medicine Tape Is Worth WatchingFive companies. One overlapping story. The race to rebuild human tissue is moving from the lab into the public markets — fast. NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- World Street Intelligence News Commentary — There are weeks when the most interesting story on Wall Street isn't a single ticker. It's the through-line connecting several of them. The week of May 21, 2026 was one of those weeks. A brand-new Nasdaq listing in regenerative tissue arrived in the middle of a cluster of earnings beats, pipeline launches, and product approvals across a handful of related names — all of them, in one way or another, telling the same story: medicine is shifting from "replace" to "regenerate," and
- SECSEC Form SD filed by Smith & Nephew SNATS Inc.SD - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- PRSmith+Nephew drives progress in chronic wound care with ALLEVYN™COMPLETE CARE Dressing and RENASYS™ EDGE tNPWT set to launch at EWMA 2026Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, continues to drive progress in chronic wound management with an industry-leading portfolio set to showcase at the upcoming European Wound Management Association (EWMA) Conference, Bremen between 6-8 May 2026. Demonstrating a long-term commitment to chronic wound management, Smith+Nephew is launching two new wound care innovations designed to support patient outcomes, simplify wound management and ease the clinical burden. This reflects the scale and urgency of a challenge that affects up to 14.9m people in Europe and consumes up to 4% of healthcare spend1. Fully supporting clinicians and patients across the continuum o
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
SNN FAQ
6 questionsWhat does Smith & Nephew SNATS Inc. do?
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as...Where does SNN stock trade?
Smith & Nephew SNATS Inc. (SNN) is listed on NYSE.What sector and industry is SNN in?
Smith & Nephew SNATS Inc. operates in the Health Care sector, Industrial Specialties industry.What are analysts saying about SNN?
Smith & Nephew SNATS Inc. has had 8 recent analyst actions on file. The most recent action was from Kepler: Hold on 2026-06-04. Recent price targets cluster around $3750.00.What companies are similar to SNN?
Notable peers in the same industry include ISRG (Intuitive Surgical Inc.), EW (Edwards Lifesciences Corporation), STE (STERIS plc (Ireland)), ZBH (Zimmer Biomet Holdings Inc.), MAS (Masco Corporation). Compare SNN side-by-side with any of them on Quantisnow.How can I track SNN on Quantisnow?
Quantisnow aggregates Smith & Nephew SNATS Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SNN to receive live email and push alerts on every new disclosure.